Ads
related to: symbicort rapihaler with spacer price range 10 0 1 23 ip address
Search results
Results From The WOW.Com Content Network
Budesonide/formoterol, sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). [2] It contains budesonide , a steroid ; and formoterol , a long-acting β 2 -agonist (LABA). [ 2 ]
An asthma inhaler works most effectively if you deliver your medication slowly, so this is where a spacer device can be useful to help you achieve this goal. Many people using metered dose ...
Budesonide/glycopyrronium bromide/formoterol, sold under the brand name Breztri Aerosphere among others, is an inhalable fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).
Spacers slow down the speed of the aerosol coming from the inhaler, meaning that less of the asthma drug impacts on the back of the mouth and somewhat more may get into the lungs. [ 2 ] [ 4 ] In the case of corticosteroids , less residue in the mouth reduces the risk of developing oral candidiasis , a yeast infection.
Recent evidence shows that nebulizers are no more effective than metered-dose inhalers (MDIs) with spacers. [5] An MDI with a spacer may offer advantages to children who have acute asthma. [ 3 ] [ 6 ] [ 5 ] Those findings refer specifically to the treatment of asthma and not to the efficacy of nebulisers generally, as for COPD for example. [ 5 ]
Inhaler for a powder based in budesonide and formoterol. Formoterol is marketed in three forms: a dry-powder inhaler (DPI), a metered-dose inhaler (MDI) and an inhalation solution, under various brand names including Atock, Atimos/Atimos Modulite, Foradil/Foradile, Fostair, Oxeze/Oxis, Perforomist and Symbicort.
Salmeterol is a long-acting β 2 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. [2]
Rubrik upsized its IPO to raise $752 million after selling 23.5 million shares, the company said in a statement. This confirmed an earlier Reuters report about the offering details.